- Home
- BLX vs AUPH Comparison
BLX vs AUPH Comparison
Compare BLX & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$16.83
Company Overview
Basic Information| Metric | BLX | AUPH |
|---|---|---|
| Founded | 1977 | 1993 |
| Country | Panama | Canada |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.1B |
| IPO Year | 1997 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BLX | AUPH |
|---|---|---|
| Price | $54.60 | $16.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $65.90 | $17.86 |
| AVG Volume (30 Days) | 124.2K | ★ 730.1K |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 0.53 |
| Revenue | N/A | ★ $283,055,000.00 |
| Revenue This Year | $10.52 | $15.83 |
| Revenue Next Year | $10.12 | $21.30 |
| P/E Ratio | ★ $8.26 | $32.60 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $38.41 | $11.89 |
| 52 Week High | $63.20 | $19.25 |
Technical Indicators
Market Signals| Indicator | BLX | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 46.11 | 56.03 |
| Support Level | $54.32 | $15.27 |
| Resistance Level | $56.04 | $17.16 |
| Average True Range (ATR) | 1.15 | 0.48 |
| MACD | 0.05 | 0.07 |
| Stochastic Oscillator | 33.44 | 71.14 |
Price Performance
Historical Comparison BLX
AUPH
About BLX Banco Latinoamericano de Comercio Exterior S.A.
Bladex Inc is a Panama-based bank focused on providing financial solutions to financial institutions and corporations throughout Panama.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.